Opioid Use Disorder Market - By Drug (Buprenorphine [Sublocade, Belbuca, Suboxone, Zubsolv], Methadone, Naltrexone), By Age, By Route of Administration (Intravenous, Oral), By Distribution Channel, Global Forecast 2023-2032

Opioid Use Disorder Market - By Drug (Buprenorphine [Sublocade, Belbuca, Suboxone, Zubsolv], Methadone, Naltrexone), By Age, By Route of Administration (Intravenous, Oral), By Distribution Channel, Global Forecast 2023-2032

Opioid Use Disorder Market Size

Opioid Use Disorder (OUD) Market size was estimated to be USD 2.8 billion in 2022 and is expected to expand at CAGR of 10.6% from 2023 to 2032. Rise in drug approvals for the treatment of opioid use disorder, increasing opioid addiction cases in developed counties, and increasing awareness for the adoption of buprenorphine patches as an effective treatment are some of the key factors driving this market.

The number of opioid addiction cases are rapidly rising every year and making opioid dependence a serious public health issue. Opioid use disorder (OUD) is a treatable, chronic disease that can affect anyone regardless of race, gender, income level, or social class. Opioids are natural, semi-synthetic, or synthetic chemicals that interact with opioid receptors in the body and brain and reduce perception of pain. Prescription opioids are meant to be used to treat acute pain (such as recovering from injury or surgery), chronic pain, active-phase cancer treatment, palliative care, and end-of-life care.
 

Covid-19 Impact

The COVID-19 outbreak is anticipated to have a mixed impact on growth of the OUD market. The pandemic has stressed healthcare system in the entire world. All medical resources were diverted towards COVID-19 patients and hence all elective surgeries were postponed during 2020. The decrease in the number of scheduled surgeries anticipated to decrease in the demand of opioids for pain management which caused decrease in the prevalence of OUD.
 

However, the cancellation of doctor’s visits increased long term usage of opioids during the pandemic. This in turn increased the prevalence of OUD disease. The overdose of opioids is a leading injury related cause of death in the US. According to CDC estimates around 2.7 million persons in the United States would suffer with OUD in 2020.  Hence, there wasn’t a significant rise in new opioid consumers, but existing users continued consumption resulted in market progress.
 

Opioid Use Disorder Market Trends

Opioids are a group of painkillers that are used to relax muscles, reduce pain, and relieve stress. The chronic, relapsing brain illness known as opioid usage disorder is characterized by excessive opioid seeking and use despite its side effects. It is regarded as a brain condition because it involves functional changes to brain circuits related to motivation, stress, self-control, and decision-making, and because those changes may endure for a considerable amount of time after drug use has stopped. An overwhelming desire to consume opioids, increased opioid tolerance, and withdrawal symptoms after cessation are all symptoms of opioid use disorder.
 

The increasing opioid prescribers, increasing awareness about OUD among population, increasing government initiatives to diagnose and treat OUD, and rise in product approvals for OUD treatment drugs anticipated to fuel the market expansion. For instance, in May 2020, Indivior PLC, a pharmaceutical company in the U.S., announced the approval of Subutex from Swedish Medical Products Agency (MPA). Subutex is a prolonged release solution available in the form of injection- 100 and 300mg for substitution treatment of opioid dependence in adults and adolescents over 16 years of age.
 

OUD Drug Market Analysis

Based on drug type, the opioid use disorder market is segmented into buprenorphine, methadone, and naltrexone. In 2022, the buprenorphine market segment held the largest market share, and this trend is predicted to continue during the forecast period. The factors that account for the highest share of the market is increased use of buprenorphine as it is an effective option to treat opioid dependence, reduce cravings, and improve the quality of life for patients undergoing addiction treatment. Buprenorphine is currently available in two forms- alone and in combination with the opioid receptor antagonist naloxone. Both formulations of buprenorphine are effective for the treatment of opioid use disorders.
 

By age group, the opioid use disorder market is segmented into 19 to 40, 41 to 60, and 61 & over. The 19 to 40 age group segment dominated the market in 2022 and is expected to continue this trend throughout the forecast period, owing to the changes in lifestyle habits as well as increased use of opioid as pain treatment in young and middle age population.
 

For instance, in 2020, national institute on drug abuse (NIDA) estimated around 2.7 million people aged 12 or older, in the US had an opioid use disorder (OUD) in the past 12 months—including 2.3 million people with a prescription opioid use disorder.
 

Based on route of administration, the opioid use disorder market is segmented into intravenous and oral. The oral segment projected to account for highest market share during the forecast period due to the availability of various types of OUD drugs in different dosages in the oral form.
 

By distribution channel, the opioid use disorder market hospital pharmacies, online pharmacies, and retail pharmacies. Hospital pharmacies segment anticipated to account for highest share in 2022.
 

Hospitals are primary care facilities with abundant presence of well trained, skilled staff and professionals who assist patients in received effective treatments.
 

North America dominated the OUD market and accounted for a revenue share of over 49.3% in 2022 owing to increase the number of product launches for treatment of opioids use disorder, increasing prescriptions of opioids, increasing opioid consumers, increasing deaths from overdose of opioids, and well-established opioid industry in North America.

Opioid Use Disorder Market Share

The key market players include

• Alkermes, Inc.
• Indivior PLC
• BioDelivery Sciences International, Inc.
• Orexo US, Inc.
• Titan Pharmaceuticals, Inc.
• Omeros Corporation
• Camurus
• Hikma Pharmaceuticals PLC
• AstraZeneca plc
• Viatris Inc.

Furthermore, players in the market constantly opt for efficient strategies to bolster their brand value as well as promote the global market growth. For instance, in December 2020, Orexo AB entered into an exclusive agreement with Accord Healthcare Limited for the commercialization of ZUBSOLVE and NALOXE sublingual tablets in Europe.

Opioid Use Disorder Market News

• In June 2022, The Titan Pharmaceuticals, Inc. entered into partnership with Indegene to establish multichannel digital marketing programme throughout the U.S. and further increase their competence in providing Probuphine implants to opioid addiction patients.
   
• In February 2021, Orexo AB announced the collaboration with ApexB.io and Magellan Rx Management to further research on the use of modia, a digital therapeutic designed for individuals with opioid use disorder (OUD), by establishing a novel, real-world evidence approach. Modia, offers individuals with OUD access to tailored, interactive psychotherapy interventions through their mobile device or computer.
   

The opioid use disorder market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Drug Type

• Buprenorphine
  • Buprenorphine alone drugs
    • Sublocade
    • Belbuca
    • Other buprenorphine brands
  • Buprenorphine combined with naloxone drugs
    • Zubsolv
    • Suboxone
    • Bunavail
    • Other combinational drug brands
• Naltrexone
• Methadone

By Age Group

• 19 to 40
• 41 to 60
• 61 and over

By Route of Administration

• Intravenous
• Oral

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe          
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific  
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific   
• Latin America         
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa          
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa